Bifidobacterium / Risk Cancer Research Results

Bif, Bifidobacterium: Click to Expand ⟱
Features: Bacteria
Bifidobacterium has been associated with improved responses to immune checkpoint inhibitors such as anti–PD-L1 antibodies. The suggested mechanisms include:
-Enhancing dendritic cell function.
-Promoting the activation and proliferation of T cells.
-Modulating cytokine profiles in a way that favors anti-tumor immunity.

Bifidobacterium is a genus of gram-positive, nonmotile, often branched anaerobic bacteria. They are ubiquitous inhabitants of the gastrointestinal tract.

Bifidobacterium longum: Gram-positive, catalase-negative, rod-shaped bacterium.

Here are several notable species:
Bifidobacterium longum
Often found in the human gastrointestinal tract, B. longum has been extensively studied for its role in modulating the immune system and improving gut barrier function. Bifidobacterium breve
Known for its anti-inflammatory properties, B. breve is used in many probiotic formulations and has been researched for its potential to alleviate gastrointestinal disorders, which may indirectly support cancer patients.
Bifidobacterium bifidum
This species is a common member of the gut microbiota and plays a role in maintaining mucosal integrity and immune modulation.
Bifidobacterium infantis
Commonly found in the intestines of breast-fed infants, B. infantis is studied for its beneficial effects on gut health and its potential to modulate immune responses.
Bifidobacterium animalis (including subspecies such as B. animalis subsp. lactis).

Widely incorporated into commercial probiotic products, this species has been researched for its role in digestive health, and emerging studies suggest potential benefits in the context of systemic health, including immune regulation.

Bifidobacterium — a genus of anaerobic, Gram-positive commensal bacteria commonly used as probiotics and studied as a microbiome-based immunomodulatory adjunct rather than a conventional cytotoxic anticancer drug. It is formally classified as a live biotherapeutic / probiotic microbial modality. Standard abbreviations are strain-specific rather than genus-wide, for example B. breve, B. bifidum, and B. longum. Its origin is the human and animal gastrointestinal microbiota, with some strains developed as probiotic formulations. In cancer research, its relevance is mainly strain-dependent and centers on gut–immune–tumor crosstalk, especially dendritic-cell activation, IL-12 signaling, CD8 T-cell priming, and possible enhancement of immune-checkpoint efficacy.

Primary mechanisms (ranked):

  1. Augmentation of dendritic-cell activation and antigen-presentation programs, including IL-12-linked antitumor immune priming.
  2. Promotion of CD8 T-cell expansion, tumor infiltration, and IFN-γ-dominant antitumor immunity.
  3. Sensitization or synergy with PD-1 or PD-L1 checkpoint blockade in preclinical models; probable microbiome biomarker role in some human immunotherapy settings.
  4. Gut barrier and mucosal immune modulation, including epithelial chemokine signaling that favors immune-cell recruitment.
  5. Secondary indirect suppression of tumor growth and increased tumor-cell apoptosis through immune-mediated rather than direct high-exposure cytotoxic mechanisms.

Bioavailability / PK relevance: Classical small-molecule PK metrics are not applicable. Activity depends on viable strain delivery, gastrointestinal survival, colonization or transient persistence, and host microbiome context. The dominant exposure compartment is intestinal; systemic anticancer effects are indirect and immune-mediated.

In-vitro vs systemic exposure relevance: This is not primarily a concentration-driven small-molecule modality. Many reported anticancer effects arise from host–microbe and gut–immune interactions in vivo, so direct in-vitro tumor-cell exposure data have limited translational meaning unless a defined metabolite or engineered strain is being studied.

Clinical evidence status: Strongest evidence for cancer relevance remains preclinical and associative. Human oncology data currently support biomarker and adjunctive-supportive roles more than established tumor-control efficacy. Randomized probiotic trials in cancer patients have mainly evaluated gastrointestinal or perioperative outcomes, with mixed but generally supportive safety and symptom data; direct RCT proof of genus-specific antitumor benefit is not established.

Mechanistic profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Dendritic-cell activation and IL-12 axis ↓ tumor support via improved antigen presentation ↑ DC activation, ↑ IL-12 G Immune priming Most central evidence is immune-mediated, not direct tumor toxicity. Strain effects are heterogeneous; B. breve data are especially notable.
2 CD8 T-cell priming and IFN-γ antitumor immunity ↓ tumor growth, ↑ apoptosis ↑ tumor-specific T-cell activation G Adaptive antitumor response Improved T-cell priming appears downstream of dendritic-cell conditioning and is a major explanation for tumor-control effects.
3 Checkpoint inhibitor sensitization ↑ sensitivity to PD-1 or PD-L1 therapy (context-dependent) ↑ immunotherapy responsiveness G Combination leverage Best supported in mouse models and human microbiome-association studies; not yet validated as a stand-alone clinical antitumor intervention.
4 Gut epithelial chemokine and barrier signaling Indirect ↓ pro-tumor inflammatory or dysbiotic signaling ↑ mucosal integrity, ↑ CCL20-mediated immune-cell recruitment R/G Host interface conditioning Gut-location effects likely precede systemic antitumor immune effects; microbiome context is a major determinant.
5 Direct tumor proliferation suppression and apoptosis ↓ TumCG, ↑ apoptosis ↔ or indirect benefit G Secondary downstream tumor control This is best interpreted as immune-mediated downstream biology rather than evidence of direct genus-wide tumor-cell cytotoxicity.
6 Clinical Translation Constraint ↔ strain-dependent ↔ host-dependent G Deployment limitation Translation is constrained by strain specificity, product quality control, colonization variability, antibiotic exposure, concurrent therapy effects, and infection risk in severely immunocompromised hosts.

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
Risk, Risk: Click to Expand ⟱
Source:
Type:
Risk: by definition reduces risk of disease or cancer.
Down Target direction of risk indicates lower cancer risk.
ChemoPreventive also mean lower cancer risk. But for Chemopreventive an up arrow indicates more preventive. 
Cancer Risk Impact Score (CRIS)
CRIS scale:
–5 = very strong risk reduction
–4 = strong risk reduction
–3 = moderate risk reduction
–2 = modest risk reduction
–1 = weak / context-dependent
0 = neutral




CRIS Exposure / Compound Evidence Cancers Notes




-5 Exercise (overall)
VStrong Hum BC, CRC, Endo, PCa, Liv






-5 Aerobic + resistance VStrong Hum Broad inc + mort






-4 Aerobic exercise (mod–vig) VStrong Hum BC, CRC, Endo






-4 Resistance training (alone) Strong Hum BC, CRC






-3 High-intensity interval training Mod–Strong Hum BC, CRC






-2 NEAT / low-intensity activity Moderate Hum CRC






-5 Cruciferous vegetable pattern Strong Hum Lung, CRC, BC, PCa






-5 Sunlight exposure (physiologic) Strong Hum CRC, BC, PCa






-4 Fasting (metabolic pattern)
Strong Mech + Hum BC, CRC, PCa 






-4 Curcumin
Hum + Pre GI, BC, PCa






-4 Sulforaphane
Hum + Pre Lung, CRC, BC






-4 PEITC
Hum + Pre Lung, CRC, PCa






-4 EGCG (tea matrix)
Strong Hum GI, PCa, BC






-4 Lycopene
Strong Hum PCa






-4 Apigenin
Pre + Diet Hum BC, PCa, CRC 






-4 Luteolin
Pre + Diet Hum Lung, CRC, BC 






-4 Kaempferol
Diet Hum Ov, Panc, Lung






-4 Fisetin
Pre + Early Hum CRC, PCa, Mel






-4 Ellagic acid → Urolithin A
Hum (microbiome) CRC, PCa, BC






-3 Omega-3 (EPA/DHA)
Strong Hum CRC, BC






-3 Vitamin D3 (supp)
Obs + RCT CRC, BC






-3 Garlic (allicin)
Mod Hum GI






-3 Mushroom beta-glucans
Hum adjunct GI, BC






-3 Melatonin
Hum + Mech BC, PCa






-3 Coffee (whole)
Strong Hum Liv, Endo






-2 Quercetin
Limited Hum Lung, CRC






-2 Resveratrol
Limited Hum CRC, BC






-2 I3C / DIM
Mod Hum BC, Cerv






-2 Thymoquinone
Early Hum BC, CRC






-2 Beta-carotene (food)
Hum Lung






-1 Vitamin K2 (MK-4/7)
Limited Hum Liv, PCa






-1 Boron
Obs PCa, Lung






0 Vitamin C (oral)
Strong Hum —






0 Genistein (soy)
Strong Hum BC, PCa






0 Selenium (diet)
Mixed Hum PCa






0 Capsaicin
Mixed Gastric






+2 Vitamin E (alpha only)
Strong RCT PCa






+2 Green tea extract (high-dose)
Case reports Liv






+4 Beta-carotene (supplement)
Strong RCT Lung (smokers)






+5 Alcohol (ethanol)
Strong Hum BC, Liv, Eso







Evidence
Hum        human data
VStrong    very strong
Strong     strong
Mod        moderate
Obs        observational
Pre        preclinical
RCT        randomized controlled trial
Mech       mechanistic
Adjunct    adjunct clinical use


Scientific Papers found: Click to Expand⟱
5628- Bif,  immuno,    Bifidobacterium modulation of tumor immunotherapy and its mechanism
- Review, Var, NA
Imm↑, Risk↓, GutMicro↑, AntiTum↑, OS↑, selectivity↑, eff↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Immune & Inflammatory Signaling ⓘ

Imm↑, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   OS↑, 1,   Risk↓, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Risk, Risk
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:44  Target#:785  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page